abstract |
Featured are methods for assessing hemostatic risk including the risk for ACS. Such methods include acquiring blood/plasma composition based on a biological sample obtained from a subject, determining parameters associated with blood clotting, simulating in silico blood clotting using the determined parameters and comparing the results of such simulation to a reference and to determine the hemostatic risk from said comparing. In further embodiments, such methods further include selecting a treatment regime or protocol based on the results of such comparing. In yet further embodiments, such methods further include assessing the efficacy of medicants, drugs and the like of a given treatment protocol such as by simulating in silico the application of such medicants, drugs and the like. |